\
&
Contact us
\
&
Contact us
Starts in 1 week from now
LocationOnline
ProgrammesThis webinar will offer a comprehensive introduction to the DUT Call 2025 and guidance on how to apply for funding.
Engage directly with the DUT Call Secretariat and get your questions answered during a Q&A session.
Representatives from participating funding agencies will also be present to explain country-specific rules and answer your questions during breakout sessions.
For more information on this online event and to register, please visit the dedicated event page via this link.
The Driving Urban Transitions (DUT) Partnership is an intergovernmental research and innovation programme addressing key challenges of urban transitions. The ambition is to shape and facilitate an innovation ecosystem that enables all urban actors to engage and benefit. With currently 67 partners from 28 countries, the DUT Partnership addresses the challenges which European cities face in their endeavour to become sustainable and enhance the quality of life for their citizens.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
